FDA reversals leave investors worrying about the fates of other experimental drugs [CNBC]
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: CNBC
The agency initially refused to review Moderna's flu shot before reversing course. Companies have accused the FDA of reversing previous guidance, leaving investors worried about the prospects for other drugs in the pipeline. FDA Commissioner Marty Makary and other leaders have publicly pledged flexibility for drugs treating rare diseases. Investors don't feel like recent moves reflect that. In this article FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington's disease from UniQure , a gene therapy for Hunter syndrome from Regenxbio and a
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- FDA vaccines chief Dr. Vinay Prasad to leave regulator in April [USA TODAY]USA TODAY
- uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QUREPR Newswire
- FDA's controversial vaccine chief will exit agency next month [CNN]CNN
- FDA Vaccine Chief Vinay Prasad Set to Leave Post Next Month [Yahoo! Finance Canada]Yahoo! Finance Canada
- FDA Vaccine Chief Vinay Prasad Set to Leave Post Next Month [Yahoo! Finance]Yahoo! Finance
QURE
Earnings
- 11/10/25 - Miss
QURE
Sec Filings
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- QURE's page on the SEC website